サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1660706

オーファンドラッグ市場レポート：薬剤タイプ、疾患タイプ、フェーズ、販売上位の薬剤、流通チャネル、地域別、2025年～2033年

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 148 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
オーファンドラッグ市場レポート：薬剤タイプ、疾患タイプ、フェーズ、販売上位の薬剤、流通チャネル、地域別、2025年～2033年
出版日: 2025年02月10日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オーファンドラッグの世界市場規模は2024年に2,373億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は9.97%で、2033年には5,825億米ドルに達すると予測しています。

オーファンドラッグとは、希少疾患の診断、予防、治療に使用される医薬品を指します。これらの医薬品は、特定の公衆衛生上の要件を満たすために製造され、少数の患者グループ向けに製造されるため、通常、市場は限られています。これらの医薬品は、多くの腫瘍学的、代謝学的、血液学的、免疫学的、感染学的、神経学的疾患に対して有効です。リンパ腫、白血病、嚢胞性線維症、神経膠腫、膵臓がん、卵巣がん、多発性骨髄腫、腎細胞がんなどの医学的疾患は、しばしば生命を脅かし、慢性的、進行性、退行性、障害性であり、特定の症状に効果的な特定の治療法が必要とされます。

オーファンドラッグの市場動向：

がんやその他の希少遺伝性疾患の有病率の増加は、市場の成長を促す重要な要因のひとつです。製薬メーカーは、患者に個別化治療を提供するために革新的な希少疾病用医薬品を開発しています。また、オーファンドラッグの利点に関する大衆の意識の高まりも市場を牽引しています。新しい医薬品メーカーの出現や、伝染病の蔓延を抑制するための政府の有利な政策の実施も、市場の成長に寄与しています。さらに、生物学的オーファンドラッグの開発など、さまざまな製品革新も成長を促す要因となっています。これらの医薬品は、がんなどの疾患を治療し、幹細胞に生じた損傷を回復させることができるため、全体的な需要を大幅に促進しています。その他の要因としては、医療インフラの改善、広範な研究開発活動などが挙げられ、市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 2024年の世界のオーファンドラッグの市場の市場規模は？
  • 2025-2033年におけるオーファンドラッグの市場の世界市場成長率は？
  • 世界のオーファンドラッグの市場を牽引する主要因は何か？
  • 世界のオーファンドラッグの市場に対するCOVID-19の影響は？
  • 世界のオーファンドラッグの市場の薬剤タイプに基づく内訳は？
  • 世界のオーファンドラッグの市場の疾患タイプ別の内訳は？
  • 世界のオーファンドラッグの市場の売れ筋別内訳は？
  • 世界のオーファンドラッグの市場の販売チャネル別内訳は？
  • 世界のオーファンドラッグの市場における主要地域は？
  • 世界のオーファンドラッグの市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のオーファンドラッグ市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 生物学的
    • 市場動向
    • 市場予測
  • 非生物学的
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患タイプ別

  • 腫瘍学
    • 市場動向
    • 市場予測
  • 血液学
    • 市場動向
    • 市場予測
  • 神経学
    • 市場動向
    • 市場予測
  • 心臓血管
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：フェーズ別

  • フェーズI
    • 市場動向
    • 市場予測
  • フェーズII
    • 市場動向
    • 市場予測
  • フェーズIII
    • 市場動向
    • 市場予測
  • フェーズIV
    • 市場動向
    • 市場予測

第9章 市場内訳：販売上位の薬剤別

  • レブラミド
    • 市場動向
    • 市場予測
  • リツキサン
    • 市場動向
    • 市場予測
  • コパキソン
    • 市場動向
    • 市場予測
  • オプジーボ
    • 市場動向
    • 市場予測
  • キイトルーダ
    • 市場動向
    • 市場予測
  • イブルビカ
    • 市場動向
    • 市場予測
  • アボネックス
    • 市場動向
    • 市場予測
  • センシパー
    • 市場動向
    • 市場予測
  • ソリリス
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Jazz Pharmaceuticals Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd
図表

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2024
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2024
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million USD), 2025-2033
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million USD), 2025-2033
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players
目次
Product Code: SR112025A2382

The global orphan drugs market size reached USD 237.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 582.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.97% during 2025-2033.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

Breakup by Drug Type:

  • Biological
  • Non-Biological

Breakup by Disease Type:

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Breakup by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Top Selling Drugs:

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.What was the size of the global orphan drugs market in 2024?
  • 2.What is the expected growth rate of the global orphan drugs market during 2025-2033?
  • 3.What are the key factors driving the global orphan drugs market?
  • 4.What has been the impact of COVID-19 on the global orphan drugs market?
  • 5.What is the breakup of the global orphan drugs market based on the drug type?
  • 6.What is the breakup of the global orphan drugs market based on the disease type?
  • 7.What is the breakup of the global orphan drugs market based on top selling drugs?
  • 8.What is the breakup of the global orphan drugs market based on the distribution channel?
  • 9.What are the key regions in the global orphan drugs market?
  • 10.Who are the key players/companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orphan Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Phase

  • 8.1 Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

  • 9.1 Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8 Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9 Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10 Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Alexion Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Amgen Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Biogen Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Bristol Myers Squibb Company
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 Jazz Pharmaceuticals Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Sanofi S.A.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Takeda Pharmaceutical Company Limited
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis
    • 16.3.14 Teva Pharmaceutical Industries Ltd
      • 16.3.14.1 Company Overview
      • 16.3.14.2 Product Portfolio
      • 16.3.14.3 Financials
      • 16.3.14.4 SWOT Analysis